Vivatides Therapeutics Raises $54M Series A to Advance Next-Gen RNA…

Team S · 2026-04-10T15:26:54.000Z

Biotechnology startup Vivatides Therapeutics has secured an oversubscribed $54 million Series A funding round, highlighting strong investor confidence in next-generation RNA therapeutics and delivery technologies. The round was co-led by Qiming Venture Partners along with a leading industry fund, with participation from Highlight Capital, TF Capital, and existing investor Apricot Capital, signaling robust backing from global healthcare-focused investors. Founded in 2025, Vivatides is focused on developing RNA-based therapeutics that target tissues beyond the liver, an area that has historically been difficult due to delivery limitations. Traditional RNA therapies have largely been confined to liver-related applications, leaving a significant gap in treating diseases affecting other organs. The company is building proprietary delivery platforms designed to enable precise targeting of extrahepatic tissues using technologies such as siRNA and antisense oligonucleotides. By improving delivery efficiency, tissue specificity, and safety, Vivatides aims to unlock new treatment possibilities across a wide range of chronic and high-prevalence diseases, including cardiovascular conditions and cancer. The newly raised capital will be used to accelerate the development of its delivery platform, advance multiple pipeline programs toward clinical trials, and expand its global research and development footprint. The company also plans to strengthen its leadership and scientific teams as it scales operations. As RNA therapeutics continue to emerge as a major modality alongside small molecules and biologics, breakthroughs in delivery technologies are becoming critical to unlocking their full potential. Vivatides is positioning itself at the forefront of this shift, targeting one of the most challenging and promising frontiers in modern drug development.

Member Login Get Access

Vivatides Therapeutics Raises $54M Series A to Advance Next-Gen RNA… | Newnex